Comparison of thromboembolic events in patients treated with Celecoxib, a Cyclooxygenase-2 specific inhibitor, versus Ibuprofen or Diclofenac

This publication has 18 references indexed in Scilit:

• Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors
  JAMA, 2001
• NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection
  The Lancet, 2001
• Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
  Arthritis & Rheumatism, 2000
• Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis
  JAMA, 1999
• Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy
  Expert Opinion on Investigational Drugs, 1999
• Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
  Proceedings of the National Academy of Sciences, 1999
• Aspirin as a Therapeutic Agent in Cardiovascular Disease
  Circulation, 1997
• Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol)
  Prostaglandins, 1989